ImmunityBio (NASDAQ:IBRX) Shares Gap Up – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX) shares gapped up before the market opened on Friday . The stock had previously closed at $7.82, but opened at $8.21. ImmunityBio shares last traded at $8.6340, with a volume of 7,906,407 shares traded.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Anktiva approvals and sales growth are driving upside expectations — Zacks highlights recent approvals, growing U.S. uptake and global launches that set up a pivotal 2026 for Anktiva. IBRX Stock: Anktiva’s Approvals and What Comes Next
• Positive Sentiment: Company may benefit from a persistent BCG shortage that could accelerate Anktiva adoption in NMIBC; Zacks flags upcoming 2026 catalysts (FDA discussions, global launches, clinical milestones). IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Positive Sentiment: Operational progress: Benzinga reports ImmunityBio completed manufacturing engineering programs for its NK-cell therapy platform — a milestone that could ease scale-up and broaden pipeline value. Why Is ImmunityBio Stock Soaring On Friday?
• Positive Sentiment: Sell-side support: BTIG initiated coverage with a Buy and $13 price target, signaling analyst confidence in further upside from current levels. Benzinga
• Neutral Sentiment: Market narrative: MarketBeat/Barron’s coverage places ImmunityBio among small biotechs benefiting from powerful oncology launches (Anktiva), underscoring both growth potential and sector risk. Why 2 Small Biotechs May Hold the Key to New Cancer Treatments (IBRX)
• Negative Sentiment: Valuation and concentration risks: Zacks flags that the rally has pushed IBRX to roughly 33x sales for Anktiva and notes the premium assumes near-perfect commercialization; reliance on one product and a large 2025 net loss are key risk points. ImmunityBio Valuation: Paying 33x Sales for Anktiva

Analysts Set New Price Targets

IBRX has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. HC Wainwright upped their target price on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Jefferies Financial Group increased their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, ImmunityBio presently has a consensus rating of “Moderate Buy” and an average price target of $14.40.

ImmunityBio Price Performance

The business’s fifty day moving average price is $6.62 and its 200 day moving average price is $3.83. The stock has a market cap of $8.63 billion, a P/E ratio of -22.08 and a beta of -0.03.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million for the quarter. On average, analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 75,000 shares of the firm’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the sale, the director directly owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. This trade represents a 2.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 501,967 shares of company stock worth $4,466,412 in the last 90 days. Company insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently bought and sold shares of IBRX. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of ImmunityBio by 347.7% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,028,921 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after buying an additional 5,837,898 shares during the period. Armistice Capital LLC bought a new position in ImmunityBio in the 2nd quarter valued at approximately $20,497,000. AlphaCore Capital LLC bought a new position in ImmunityBio in the 2nd quarter valued at approximately $7,854,000. Finally, Rafferty Asset Management LLC boosted its position in ImmunityBio by 79.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 452,458 shares of the company’s stock worth $1,113,000 after buying an additional 199,990 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.